Diabetes Charter Calls for Patient Control of Device Data

An 18-month international effort produced a framework giving people with diabetes greater say over data from glucose monitors and insulin pumps.

Updated on Nov. 18, 2026 in Diabetes

Bold flat-color editorial illustration of a white sensor pod on a navy field, with a teal line passing through an open gate, evoking patient control over device data.
An international charter released Tuesday calls for people with diabetes to control data from glucose monitors and insulin pumps, following Dexcom's bundled-consent dispute. AI Illustration. Upload story photo >

Live Poll

Do you trust medical device companies to handle your health data responsibly?

An international Diabetes Data Rights Charter has been released, calling for people with diabetes to have greater control over data generated by glucose monitors and insulin pumps. The move follows a dispute in which Dexcom pushed users to accept updated terms or stop using its app, prompting lawsuits and public criticism.

Why it matters

The Charter addresses unresolved questions about who owns device-generated health data and how much access patients have to it. Its standards extend beyond existing legal rights, offering a reference point for how smart medical devices handle patient information worldwide.

The Charter was produced over an 18-month international process and organized around five principles: data access, privacy and security, benefits and interests, choice and control, and accountability and transparency. It is described as compatible with the EU and UK GDPR and the US HIPAA, but whether device makers will adopt it has not been stated.

The players

Dexcom

Dexcom is a publicly traded American maker of continuous glucose monitoring systems used by people with diabetes.

The details

The Charter rejects bundled consent, which ties essential device functions to broad data sharing. The release follows Dexcom's in-app notification requiring users to accept updated terms or discontinue use of the app, a move that drew lawsuits and public outcry from the global diabetes community.

Timeline

  1. Over an 18-month period, the Charter was developed through international collaboration.

  2. Roughly 10 years ago, patient records shifted from paper logs to device-generated data.

Big Picture

The Charter is positioned as going beyond the EU and UK GDPR and the US HIPAA, which set legal baselines for health data, by articulating best-practice standards for diabetes device data specifically.

People using continuous glucose monitors or insulin pumps may gain clearer rights over the data their devices generate, including the ability to decline data sharing that is not needed for device function. The Charter's principles could shape the terms patients are asked to accept when using these tools.

The takeaway

Patients using connected diabetes devices should review data-sharing terms carefully and understand their right to access and control the information their devices generate. Choosing products whose makers commit to transparent data practices can help protect personal health information.

Further reading

Explore more on Diabetes to see how device data and patient care are evolving.

Source note: This article includes information reported by Eurasia Review.

Live Poll

Do you trust medical device companies to handle your health data responsibly?